echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yuheng Pharmaceuticals intends to invest $1.6 billion to control third-party service providers

    Yuheng Pharmaceuticals intends to invest $1.6 billion to control third-party service providers

    • Last Update: 2021-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yu Heng Pharmaceuticals disclosed today that the company held a board of directors on the 18th authorized Chairman Zhu Jiman and Bow Jing, Changshu City Asia New Investment Management Center (Limited Partnership) signed the "Acquisition Framework Agreement", the company intends to acquire Bow Jing and other holdings of 70% of the Shanghai Yixin Information Technology (Group) Co., Ltd., the transaction price of about 1.6 billion yuan.
    According to the announcement, the Group belongs to a third-party collection and outsourcing service organization, for third-party payment institutions (including but not limited to Zhonghui, Lacala, Haike accommodation, pay door-to-door) to expand and sell POS terminal equipment, thereby obtaining the collection platform service fee. Business includes, but is not limited to, bank card collection business, online code-sweeping payment business, UnionPay express payment business, etc., of which the main business is the market-side service business of bank card collection business. Yan Cheng Group by a number of industry-qualified agents, is the industry's first and only successful operation of the agent group, business covers 24 provinces, with a large number of merchant resources and personal user resources, with agents, direct business two models of promotion channels.
    From the financial data, the group has experienced rapid expansion over the past year, with total assets of 261 million yuan and owner's equity of 164 million yuan at the end of October 2017, and operating income of 397 million yuan and net profit of 137 million yuan in the first 10 months of this year. At the end of 2016, the group's total assets were only 46.87 million yuan, with owner's equity of 19.78 million yuan, and 2016 full-year operating income was 64.9 million yuan, with a net profit of 16.01 million yuan. At the end of 2016, the group had 15 holding subsidiaries, and 16 new holding subsidiaries were added in the first quarter of this year, the statement said.
    Yuheng Pharmaceuticals has set three preconditions for the acquisition: first, the target company already owns 100% of all of its controlling subsidiaries;
    to all existing shareholders of the Group, the net profit attributable to the parent company of the target company, audited in 2018, 2019 and 2020, in accordance with the principle of before and after deducting non-recurring profit and loss, was RMB350 million, RMB 550 million and RMB900 million, respectively. (Shanghai Securities News)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.